Clinical trials: Melphalan
Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
This phase I trial investigates the side effects and effectiveness of chemotherapy followed by a donor (allogeneic) stem cell transplant when given to patients with high grade brain cancer.
- Conditions
- Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor, Choroid Plexus Carcinoma
- Trial name
- NCT04521946
- Testing
- Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation
- Volunteers
- healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Diseases, Hematologic Malignancy
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
This is a Phase II trial testing disease-specific myeloablative conditioning regimens for preparatory cytoreduction of patients receiving allogeneic HLA-compatible related or unrelated transplants of GCSF-mobilized peripheral…
- Conditions
- Hematologic Diseases, Hematologic Malignancy, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- 2019-KOE-001 (NCT04282174)
- Testing
- CliniMACS, Bone Marrow Transplant, Hyperfractionated Total Body Irradiation
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Baptist Health South Florida
Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
Background: Blood cancers (such as leukemias or lymphomas) often do not respond to standard treatments. A transplant of blood stem cells from a healthy donor can help people with these cancers.
- Trial name
- NCT05436418
- Testing
- Melphalan, Sirolimus, Total Body Irradiation (TBI)
- Where
- 2 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Hodgkin Lymphoma
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard of care reduced intensity regimen and an allogeneic stem cell transplant (from another person, related or unrelated).
- Trial name
- NCT02098512
- Testing
- Brentuximab Vedotin, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- New York Medical College
Severe Aplastic Anemia
Clinical Study on Modified Allogeneic Hematopoietic Stem Cell Transplantation Regimen for Severe Aplastic Anemia
The aim of this study was to evaluate the safety and efficacy of a modified allogeneic hematopoietic stem cell transplantation regimen for aplastic anemia.
- Trial name
- NCT06378060
- Testing
- Modified transplantation system
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hematology department of the 920th hospital
Hematologic Malignancy
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies
This is a phase I, prospective clinical trial studying the safety and feasibility of providing early memory T-cell DLI. The primary objective is: To assess the safety and feasibility of early CD45RA-depleted DLI administration.
- Trial name
- NCT07052370
- Testing
- Thymoglobulin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital